First steps for Bionomics' anti-anxiety drug
Wednesday, 09 July, 2008
Bionomics [ASX: BNO] has completed GMP synthesis of its anxiety drug candidate BNC210, one of the first stages in its preparation for an IND application from the US FDA.
Pharmaceutical manufacturing contractors Sai Advantium completed the Good Manufacturing Practice (GMP) synthesis, and samples they have produced will be used in the final round of toxicological testing before human trials commence.
To successfully complete GMP synthesis all operational methodologies and procedures involved in creating the drug must be demonstrated to perform their intended function.
BNC210 is part of Bionomics' MultiCore technology platform. The company recently announced a major deal with Merck Serono to develop its potassium ion channel inhibitor kvl.3, and is in clinical trials for its vascular disruption agent BNC105.
Newborns have elevated levels of an Alzheimer's biomarker
What do the brains of newborns and patients with Alzheimer's disease have in common? Both...
Cannabis use may double risk of cardiovascular disease death
Cannabis users have a 29% higher risk of acute coronary syndrome, a 20% higher risk of stroke,...
Space conditions can lead to periodontitis, scientists say
Living in zero gravity can lead to periodontitis — a serious condition where the gums...
